Geode Capital Management, LLC Lexicon Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,523,971 shares of LXRX stock, worth $3.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,523,971

Previous 3,250,535 8.41%

Holding current value

$3.84 Million

Previous $5.46 Million 1.32%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.51 - $2.39 $412,888 - $653,512	273,436 Added 8.41%	3,523,971 $5.53 Million
Q2 2024 Aug 09, 2024	BUY	$1.54 - $2.28 $1.33 Million - $1.96 Million	861,398 Added 36.05%	3,250,535 $5.46 Million
Q1 2024 May 13, 2024	BUY	$1.3 - $3.58 $52,287 - $143,991	40,221 Added 1.71%	2,389,137 $5.73 Million
Q4 2023 Feb 13, 2024	BUY	$1.0 - $1.53 $222,779 - $340,851	222,779 Added 10.48%	2,348,916 $3.59 Million
Q3 2023 Nov 13, 2023	BUY	$1.06 - $2.33 $302,842 - $665,681	285,700 Added 15.52%	2,126,137 $2.32 Million
Q2 2023 Aug 11, 2023	BUY	$2.15 - $3.49 $247,310 - $401,447	115,028 Added 6.67%	1,840,437 $4.21 Million
Q1 2023 May 15, 2023	BUY	$1.99 - $2.68 $233,761 - $314,814	117,468 Added 7.31%	1,725,409 $4.19 Million
Q4 2022 Feb 13, 2023	BUY	$1.8 - $2.56 $70,054 - $99,632	38,919 Added 2.48%	1,607,941 $3.07 Million
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $441,561 - $780,698	227,609 Added 16.97%	1,569,022 $3.77 Million
Q2 2022 Aug 12, 2022	BUY	$1.31 - $2.69 $109,449 - $224,746	83,549 Added 6.64%	1,341,413 $2.5 Million
Q1 2022 May 13, 2022	BUY	$1.95 - $3.89 $117,243 - $233,886	60,125 Added 5.02%	1,257,864 $2.63 Million
Q4 2021 Feb 11, 2022	BUY	$3.81 - $6.16 $14,542 - $23,512	3,817 Added 0.32%	1,197,739 $4.72 Million
Q3 2021 Nov 12, 2021	SELL	$3.38 - $5.35 $293,154 - $464,016	-86,732 Reduced 6.77%	1,193,922 $5.74 Million
Q2 2021 Aug 13, 2021	BUY	$4.12 - $5.87 $834,283 - $1.19 Million	202,496 Added 18.78%	1,280,654 $5.88 Million
Q1 2021 May 12, 2021	BUY	$3.45 - $9.09 $1.06 Million - $2.8 Million	308,570 Added 40.1%	1,078,158 $6.33 Million
Q4 2020 Feb 12, 2021	SELL	$1.05 - $3.67 $5,637 - $19,704	-5,369 Reduced 0.69%	769,588 $2.63 Million
Q3 2020 Nov 13, 2020	SELL	$1.44 - $2.1 $63,241 - $92,227	-43,918 Reduced 5.36%	774,957 $1.12 Million
Q2 2020 Aug 13, 2020	BUY	$1.75 - $2.3 $232,002 - $304,917	132,573 Added 19.32%	818,875 $1.63 Million
Q1 2020 May 14, 2020	BUY	$1.8 - $4.28 $29,097 - $69,186	16,165 Added 2.41%	686,302 $1.34 Million
Q4 2019 Feb 13, 2020	SELL	$3.16 - $5.15 $4,528 - $7,379	-1,433 Reduced 0.21%	670,137 $2.78 Million
Q3 2019 Nov 12, 2019	BUY	$1.2 - $6.66 $22,305 - $123,796	18,588 Added 2.85%	671,570 $2.02 Million
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $159,761 - $212,318	29,862 Added 4.79%	652,982 $4.11 Million
Q1 2019 May 14, 2019	BUY	$4.36 - $7.94 $253,032 - $460,797	58,035 Added 10.27%	623,120 $3.46 Million
Q4 2018 Feb 13, 2019	BUY	$6.15 - $10.51 $84,033 - $143,608	13,664 Added 2.48%	565,085 $3.75 Million
Q3 2018 Nov 13, 2018	BUY	$10.32 - $13.06 $239,950 - $303,658	23,251 Added 4.4%	551,421 $5.88 Million
Q2 2018 Aug 14, 2018	BUY	$7.8 - $13.69 $596,138 - $1.05 Million	76,428 Added 16.92%	528,170 $6.34 Million
Q1 2018 May 15, 2018	BUY	$7.86 - $11.39 $62,274 - $90,242	7,923 Added 1.79%	451,742 $3.87 Million
Q4 2017 Feb 13, 2018	BUY	$8.77 - $12.28 $97,952 - $137,155	11,169 Added 2.58%	443,819 $4.38 Million
Q3 2017 Nov 14, 2017	BUY	$12.17 - $16.3 $119,606 - $160,196	9,828 Added 2.32%	432,650 $5.32 Million
Q2 2017 Aug 14, 2017	BUY	N/A	422,822	422,822 $6.96 Million

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $206M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Lexicon Pharmaceuticals, Inc. Transaction History